Rosiglitazone maleate in combination with metformin hydrochloride (Avandamet drug, GlaxoSmithKline) has been approved for long-term control of glucose levels in patients with type 2 diabetes. The additive effect of the two drugs has been found to reduce hemoglobin A1c levels more than the action of tablet metformin alone. (A high hemoglobin A1c score is associated with the risk of diabetes.) Intended for use as an adjunct to exercise and diet, this “two-in-one” therapy offers cost savings and simplified dosing.
For a full description of this drug, see the Pharmaceutical-Approval Update feature in this issue.